作者
Andrew Mujugira, Amalia S Magaret, Connie Celum, Jared M Baeten, Jairam R Lingappa, Rhoda Ashley Morrow, Kenneth H Fife, Sinead Delany-Moretlwe, Guy de Bruyn, Elizabeth A Bukusi, Etienne Karita, Saidi Kapiga, Lawrence Corey, Anna Wald, Partners in Prevention HSV/HIV Transmission Study Team, Connie Celum, Anna Wald, Jairam Lingappa, Jared M Baeten, Mary Campbell, Lawrence Corey, Robert W Coombs, James P Hughes, Amalia Magaret, M Juliana McElrath, Rhoda Morrow, James I Mullins, David Coetzee, Kenneth Fife, Edwin Were, Max Essex, Joseph Makhema, Elly Katabira, Allan Ronald, Kayitesi Kayitenkore, Etienne Karita, Elizabeth Bukusi, Craig Cohen, William Kanweka, Susan Allen, Bellington Vwalika, Saidi Kapiga, Rachel Manongi, Carey Farquhar, Grace John-Stewart, James Kiarie, Mubiana Inambao, Orange Farm, Sinead Delany-Moretlwe, Helen Rees, Guy de Bruyn, Glenda Gray, James McIntyre, Nelly Rwamba Mugo
发表日期
2013/11/1
期刊
The Journal of infectious diseases
卷号
208
期号
9
页码范围
1366-1374
出版商
Oxford University Press
简介
Background. Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2–serodiscordant heterosexual couples by 48%. Whether suppressive therapy reduces HSV-2 transmission from persons coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) is unknown.
Methods. Within a randomized trial of daily acyclovir 400 mg twice daily in African HIV-1 serodiscordant couples, in which the HIV-1–infected partner was HSV-2 seropositive, we identified partnerships in which HIV-1–susceptible partners were HSV-2 seronegative to estimate the effect of acyclovir on risk of HSV-2 transmission.
Results. We randomly assigned 911 HSV-2/HIV-1–serodiscordant couples to daily receipt of acyclovir or placebo. We observed 68 HSV-2 seroconversions, 40 and 28 in …
学术搜索中的文章
A Mujugira, AS Magaret, C Celum, JM Baeten… - The Journal of infectious diseases, 2013
